Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 8/20 | 0.40 |
| ▸ | PPARA | Q07869 | 7/20 | 0.39 |
| ▸ | PPARD | Q03181 | 5/20 | 0.39 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.38 |
| ▸ | CCR3 | P51677 | 2/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333221 | 0.94 | CYP11B1 (0.43) | GPR34MAOBPPARGPPARAPPARD | |
| SCHEMBL6650894 | 0.91 | ALDH1A1 (0.47) | SMN1; SMN2PPARGPPARAPPARDADAMTS4 | |
| SCHEMBL4342666 | 0.90 | PPARG (0.39) | PPARGPPARAPPARD | |
| SCHEMBL4329073 | 0.89 | FFAR1 (0.37) | GPR34MAOBPPARGPPARAPPARD | |
| SCHEMBL4335811 | 0.89 | PPARD (0.44) | PPARGPPARAPPARDMMP13 | |
| SCHEMBL4341191 | 0.88 | PPARG (0.42) | PPARGPPARAPPARDPRMT5WDR77 | |
| SCHEMBL4341208 | 0.87 | NR2E1 (0.40) | GPR34SMN1; SMN2MAOBPPARGPPARA | |
| SCHEMBL4334574 | 0.86 | PPARG (0.48) | PPARGPPARAPPARD | |
| SCHEMBL4334569 | 0.86 | PPARG (0.48) | PPARGPPARAPPARD | |
| SCHEMBL4334564 | 0.86 | PPARG (0.48) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | GPR34 701/4885SMN1; SMN2 3054/4885MAOB 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.